Clinical trials: Cell Free DNA
Endometriosis, Cell Free DNA
Cell Free DNA Quantification in Patients With Endometriosis Followed Witd Medical Assistance to Procreation
Endometriosis is a common benign disease in premenopausal women and causes chronic pelvic pain and infertility. This infertility may be due to pelvic adhesions and surgery but also because of poor oocyte quality.
- Trial name
- ENDO-FIV (NCT05815134)
- Testing
- blood sample
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Neoplasms, Cancer
PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection
Liquid biopsy technology based on cell-free nucleic acids and protein characteristics has unique advantages and significant application prospects in cancer early detection.
- Trial name
- PROFUTURE (NCT05874648)
- Testing
- Multi-cancer early detection test
- Where
- China
- Volunteers
- 3,830 people, healthy volunteers welcome
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Breast Cancer
CIrCuLAting Dna ESr1 Gene Mutations Analysis
The estrogen-dependent nature of breast cancer was first reported in 1896 with the publication of George Beatson's observations on the regression of breast cancer following oophorectomy.
- Trial name
- CICLADES (NCT03318263)
- Testing
- next-generation sequencing (NGS)
- Where
- 10 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut de Cancérologie de Lorraine
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
The purpose of this study is to determine whether biomarkers could be found to gain more insight in tumor characteristics in order to predict which patients will have a high chance of a long progression-free survival.
- Trial name
- NCT02109913
- Testing
- Everolimus plus Exemestane
- Where
- 28 sites in Netherlands
- Volunteers
- 175 people
- Sponsor
- Amsterdam UMC, location VUmc
Hepatocellular Carcinoma, Cirrhosis
Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis
Brief Summary (Plain-Language Version - Compliant with ClinicalTrials.gov Guidelines) The goal of this observational study is to learn whether a blood test called methylated SEPT9 (mSEPT9) can help diagnose hepatocellular…
- Trial name
- SEPT9_CROSS (NCT03311152)
- Testing
- "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany)
- Where
- France
- Volunteers
- 639 people
- Sponsor
- Central Hospital, Nancy, France
Endometrial Cancer, Liquid Biopsy
Cell-free DNA Methylation for Endometrial Cancer
Liquid biopsy is challenging for the diagnosis of endometrial cancer. In this study, investigators perform the methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177, in the peripheral serum to discover the…
- Conditions
- Endometrial Cancer, Liquid Biopsy, DNA Methylation, Cervical Cytology
- Trial name
- NCT04651738
- Testing
- DNA methylation testing
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Lei Li
Neoplasms, Solid Tumor
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
DNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict…
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Lung Neoplasms
- Trial name
- METHYLSCAPE-CO (NCT07741435)
- Testing
- Methylscape DNA methylation assay
- Where
- Colombia
- Volunteers
- 3,250 people, healthy volunteers welcome
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Maternal Neoplasia
IDENTIFY Study: Natural History of Maternal Neoplasia
Background: Pregnant women can get a DNA analysis of their blood. The test tells a woman and her doctor about the DNA of her unborn baby. But some women get test results that are abnormal or not reportable.
- Trial name
- NCT04049604
- Testing
- NIPT
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Gastric Cancer, Gastro-oesophageal Junction Cancer
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or…
- Trial name
- NCT03957564
- Testing
- Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Qinghai University
Heart Transplant Failure and Rejection
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
The study objective is to demonstrate that rejection surveillance of heart transplant recipients with Prospera dd-cfDNA is non-inferior to rejection surveillance with endomyocardial biopsy and histology in the first…
- Trial name
- DETECT (NCT05081739)
- Testing
- Prospera Transplant Assessment, Endomyocardial biopsy
- Sponsor
- Natera, Inc.
Acute Kidney Injury, Renal Transplantation
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a potential diagnostic tool to monitor the rejection status of the kidney transplant.
- Trial name
- DART-REIN (NCT06026592)
- Testing
- determination of circulating biomarkers of renal origin circulating biomarkers of renal origin
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thoracic Organ Transplantation
Genome Transplant Dynamics
Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early.
- Trial name
- NCT02423070
- Where
- 7 sites in United States
- Volunteers
- 991 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lung Carcinoma
Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
This clinical trial investigates how practical and doable (feasibility) cell-free deoxyribonucleic acid (DNA) liquid biopsy is in screening high-risk patients for lung cancer.
- Trial name
- NCT05384769
- Testing
- Liquid Biopsy, Low Dose Computed Tomography of the Chest, Survey Administration
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
Urothelial carcinoma is the most common cancer of the urinary system. It includes bladder cancer and upper urinary tract cancer, which starts in the kidney pelvis or ureter.
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer
- Trial name
- NCT07888374
- Where
- China
- Volunteers
- 477 people
- Sponsor
- Ruijin Hospital
Hereditary Cancer Syndrome
CfDNA in Hereditary And High-risk Malignancies 2
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes.
- Trial name
- CHARM2 (NCT06726642)
- Testing
- Cell-free DNA analysis
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- University Health Network, Toronto
Mature B-Cell Lymphoma
Cell Free DNA in Mature B-cell Lymphoma
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
- Trial name
- NCT04088422
- Testing
- peripheral blood collection
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Ruijin Hospital
Hepatocellular Carcinoma
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Circulating free cell DNA (cfDNA) is extracellular fragmentation of nucleic acids that occurs both in plasma and serum. This kind of DNA which derived from the apoptotic/necrotic cells or the lysis of circulating tumor cells…
- Trial name
- NCT02036216
- Where
- 2 sites in United States, China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Complication, Quality of Life
Open D3 Right Hemicolectomy Compared to Laparoscopic CME for Right Sided Colon Cancer
The primary focus in this study is to investigate and improve the surgical technique. In addition the collection of clinical data during diagnostic and follow up and the collection of tumor and blood gives us the opportunity to…
- Conditions
- Complication, Quality of Life, Surgical Procedure, Unspecified, Lymph Node Metastases
- Trial name
- D3/CME (NCT03776591)
- Testing
- Open surgery, Right colectomy, Laparoscopic surgery
- Where
- Norway
- Volunteers
- 128 people
- Sponsor
- Haraldsplass Deaconess Hospital